Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase

Journal of Medicinal Chemistry

Volumn 54, Issue 8, 2011, Pages 3037-3050

  Hwang, Sung Hee ^a   Wagner, Karen M ^a   Morisseau, Christophe ^a   Liu, Jun Yan ^a   Dong, Hua ^a   Wecksler, Aaron T ^a   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [3 (3 ADAMANTAN 1 YLUREIDO)PROPYL] 5 PHENYLPYRAZOL 1 YL]BENZENESULFONAMIDE; 4 [3 [3 (3 CYCLOHEPTYLUREIDO)PROPYL] 5 PHENYLPYRAZOL 1 YL]BENZENESULFONAMIDE; 4 [3 [3 [3 (4 CHLOROPHENYL)UREIDO]PROPYL] 5 PHENYLPYRAZOL 1 YL]BENZENESULFONAMIDE; 4 [5 PHENYL 3 [3 (3 PHENYLUREIDO)PROPYL]PYRAZOL 1 YL]BENZENESULFONAMIDE; 4 [5 PHENYL 3 [3 [3 (3 TRIFLUOROMETHYLPHENYL)UREIDO]PROPYL]PYRAZOL 1 YL]BENZENESULFONAMIDE; 4 [5 PHENYL 3 [3 [3 (4 TRIFLUOROMETHOXYPHENYL)UREIDO]PROPYL]PYRAZOL 1 YL]BENZENESULFONAMIDE; 4 [5 PHENYL 3 [3 [3 (4 TRIFLUOROMETHYLPHENYL)UREIDO]PROPYL]PYRAZOL 1 YL]BENZENESULFONAMIDE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPOXIDE HYDROLASE; INDOMETACIN; LIPOPOLYSACCHARIDE; PYRAZOLE DERIVATIVE; RECOMBINANT ENZYME; ROFECOXIB; UNCLASSIFIED DRUG; UREA;

ALLODYNIA; AREA UNDER THE CURVE; ARTICLE; DRUG HALF LIFE; DRUG SYNTHESIS; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; CYCLOOXYGENASE 2; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HYDROGEN BONDING; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PYRAZOLES; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 79955428056     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2001376     Document Type: Article

References (57)

1. Green, G. A. Understanding NSAIDs: From aspirin to COX-2 Clin. Cornerstone 2001, 3, 50-59
2. Poff, C. D.; Balazy, M. Drugs that target lipoxygenases and leukotrienes as emerging therapies for asthma and cancer Curr. Drug Targets Inflammation Allergy 2004, 3, 19-33 (Pubitemid 38854887)
3. Hyde, C. A. C.; Missailidis, S. Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumor-angiogenesis Int. Immunopharmacol. 2009, 9, 701-715
4. De Gaetano, G.; Donati, M. B.; Cerletti, C. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors Trends Pharmacol. Sci. 2003, 24, 245-252 (Pubitemid 36588873)
5. Koontongkaew, S.; Monthanapisut, P.; Saensuk, T. Inhibition of arachidonic acid metabolism decreases tumor cell invasion and matrix metalloproteinase expression Prostaglandins Other Lipid Mediators 2010, 93, 100-108
6. Hyde, C. A. C.; Missailidis, S. Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumor-angiogenesis Int. Immunopharmacol. 2009, 9, 701-715
7. Julémont, F.; Dogné, J. M.; Pirotte, B.; de Leval, X. Recent development in the field of dual COX/5-LOX inhibitors Mini-Rev. Med. Chem. 2004, 4, 633-638 (Pubitemid 38961228)
8. Charlier, C.; Michaux, C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer nonsteroidal anti-inflammatory drugs Eur. J. Med. Chem. 2003, 38, 645-659 (Pubitemid 36980661)
9. 2 Synthase-1 J. Pharmacol. Exp. Ther. 2008, 326, 975-982
10. Janusz, J. M.; Young, P. A.; Ridgeway, J. M.; Scherz, M. W.; Enzweiler, K.; Wu, L. New Cyclooxygenase-2/5-Lipoxygenase Inhibitors. Part 1. 7- tert -Butyl-2,3-dihydro-3,3-dimethylbenzofuran Derivatives as Gastrointestinal Safe Antiinflammatory and Analgesic Agents: Discovery and Variation of the 5-Keto Substituent J. Med. Chem. 1998, 41, 1112-1123 (Pubitemid 28207387)
11. Kirchner, T.; Argentieri, D. C.; Barbone, A. G.; Singer, M.; Steber, M. Evaluation of the Anti-inflammatory Activity of a Dual Cyclooxygenase-2 Selective/5-Lipoxygenase Inhibitor, RWJ 63556, in a Canine Model of Inflammation J. Pharmacol. Exp. Ther. 1997, 282, 1094-1101 (Pubitemid 27340216)
12. Barbey, S.; Goossens, L.; Taverne, T.; Cornet, J.; Choesmel, V.; Rouaud, C.; Gimeno, G.; Yannic-Arnoult, S.; Michaux, C.; Charlier, C.; Houssin, R.; Hénichart, J.-P. Synthesis and Activity of a New Methoxytetrahydropyran Derivative as Dual Cyclooxygenase-2/5-Lipoxygenase Inhibitor Bioorg. Med. Chem. Lett. 2002, 12, 779-782 (Pubitemid 34164617)
13. Praveen Rao, P. N.; Chen, Q.-H.; Knaus, E. E. Synthesis and Structure-Activity Relationship Studies of 1,3-Diarylprop-2-yn-1-ones: Dual Inhibitors of Cyclooxygenases and Lipoxygenases J. Med. Chem. 2006, 49, 1668-1683 (Pubitemid 43376511)
14. Pommery, N.; Taverne, T.; Telliex, A.; Goossens, L.; Charlier, C.; Pommery, J.; Goossens, J. -F.; Houssin, R.; Durant, F.; Hénichart, J. -P. New COX-2/5-LOX Inhibitors: Apoptosis-Inducing Agents Potentially Useful in Prostate Cancer Chemotherapy J. Med. Chem. 2004, 47, 6195-6206 (Pubitemid 39587244)
15. Liu, J.-Y; Li, N.; Yang, J.; Li, N.; Qiu, H.; Ai, D.; Chiamvimonvat, N.; Zhu, Y.; Hammock, B. D. Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 17017-17022
16. Capdevila, J. H.; Falck, J. R.; Harris, R. C. Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase J. Lipid Res. 2000, 41, 163-181 (Pubitemid 30117856)
17. Spector, A. A.; Norris, A. W. Action of epoxyeicosatrienoic acids on cellular function Am. J. Physiol. Cell Physiol. 2007, 292, C996-C1012
18. Chaudhary, K. R.; Pharm, B.; Abukhashim, M.; Hwang, S. H.; Hammock, B. D. Inhibition of Soluble Epoxide Hydrolase by trans -4-[4-(3-Adamantan-1-yl- ureido)-cyclohexyloxy]-benzoic Acid Is Protective Against Ischemia-Reperfusion Injury J. Cardiovasc. Pharmacol. 2010, 55, 67-73
19. Li, N.; Liu, J.-Y.; Timofeyev, V.; Qiu, H.; Hwang, S. H.; Tuteja, D.; Lu, L.; Yang, J.; Mochida, H.; Low, R.; Hammock, B. D.; Chiamvimonvat, N. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: insight gained using metabolomic approaches J. Mol. Cell. Cardiol. 2009, 47, 835-845
20. Node, K.; Huo, Y.; Ruan, X.; Yang, B.; Spiecker, M.; Ley, K.; Zeldin, D. C.; Liao, J. K. Anti-inflammatory Properties of Cytochrome P450 Epoxygenase-Derived Eicosanoids Science 1999, 285, 1276-1279 (Pubitemid 29398616)
21. Campbell, W. B. New role for epoxyeicosatrienoic acids as anti-inflammatory mediators Trends Pharmacol. Sci. 2000, 21, 125-127
22. Inceoglu, B.; Jinks, S. L.; Ulu, A.; Hegedus, C. M.; Georgi, K.; Schmelzer, K. R.; Wagner, K.; Jones, P. D.; Morisseau, C.; Hammock, B. D. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 18901-18906
23. Spector, A. A.; Fang, X.; Snyder, G. D.; Weintraub, N. L. Epoxy-eicosatrienoic acids (EETs): metabolism and biochemical function Prog. Lipid Res. 2004, 43, 55-90 (Pubitemid 37433867)
24. Dannhard, G.; Kiefer, W. Cyclooxygenase inhibitors-current status and future prospects Eur. J. Med. Chem. 2001, 36, 109-126 (Pubitemid 32304514)
25. Carter, J. S. Inhibitors of cyclooxygenase-2: November 1999-April 2000 Exp. Opin. Ther. Pat. 2000, 10, 1011-1020 (Pubitemid 30420883)
26. Talley, J. J. Selective Inhibitors of Cyclooxygenase-2 (COX-2) Prog. Med. Chem. 1999, 36, 201-234
27. Rao, P. N. P.; Knaus, E. E. Evolution of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Cyclooxygenase (COX) Inhibition and Beyond J. Pharm. Pharm. Sci. 2008, 11, 81s-110s
28. Rouzer, C. A.; Marnett, L. J. Cyclooxygenases: structural and functional insights J. Lipid Res. 2009, 50, S29-S34
29. Fries, J. F. NSAID Gastropathy: Epidemiology J. Musculoskeletal Med. 1991, 8, 21-28
30. For a review, see: Reitz, D. B.; Seibert, K. Selective Cyclooxygenase Inhibitors Annu. Rep. Med. Chem. 1995, 30, 179-188
31. Meyer-Kirchrath, J.; Schror, K. Cyclooxygenase-2 Inhibition and Side-Effects of Nonsteroidal Antiinflammatory Drugs in Gastrointestinal Tract Curr. Med. Chem. 2000, 7, 1121-1129
32. FitzGerald, G. A. Coxibs and Cardiovascular Disease N. Engl. J. Med. 2004, 351, 1709-1711
33. Williams, J. M.; Murphy, S.; Burke, M.; Roman, R. J. 20- Hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension J. Cardiovasc. Pharmacol. 2010, 56, 336-344
34. Schmelzer, K. R.; Inceoglu, B.; Kubala, L.; Kim, I, -H.; Jinks, S. L.; Eiserich, J. P.; Hammock, B. D. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 13646-13651 (Pubitemid 44413961)
35. Frantz, S. The trouble with making combination drugs Nature Rev. 2006, 5, 881-882 (Pubitemid 44667856)
36. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands Drug Discovery Today 2004, 9, 641-651 (Pubitemid 38981718)
37. Morphy, J. R.; Rankovic, Z. Designed multiple ligands, an emerging drug discovery paradigm J. Med. Chem. 2005, 48, 6523-6543 (Pubitemid 41504710)
38. Morphy, R.; Rankovic, Z. The physicochemical challenges of designing multiple ligands J. Med. Chem. 2006, 49, 4961-4970 (Pubitemid 44201054)
39. Morphy, R.; Rankovic, Z. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm J. Med. Chem. 2005, 48, 6523-6543 (Pubitemid 41504710)
40. Sreedhar, D.; Subramanian, G.; Udupa, N. Combination drugs: Are they rational? Curr. Sci. India 2006, 91, 406 (Pubitemid 44387151)
41. Marino, J. P.; Brooks, C. A.; Eidam, P.; Mcatee, J. J. sEH and 11β-HSD1 Dual Inhibitors. PCT/US2009/051678, July 24, 2009.
42. Copeland, R. A.; William, J. M.; Glannaras, J.; Nurnberg, S.; Covington, M.; Pinto, D.; Pick, S.; Trzaskos, J. M. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 11202-11206
43. Marino, J. P. Soluble Epoxide Hydrolase, A Target with Multiple Opportunities for Cardiovascular Drug Discovery Curr. Top. Med. Chem. 2009, 9, 452-463
44. Pommery, N.; Taverne, T.; Telliez, A.; Goossens, L.; Charlier, C.; Pommery, J.; Goossens, J.-F.; Houssin, R.; Durant, F.; Hénichart, J.-P. New COX-2/5-LOX Inhibitors: Apoptosis-Inducing Agents Potentially Useful in Prostate Cancer Chemotherapy J. Med. Chem. 2004, 47, 6195-6206 (Pubitemid 39587244)
45. Talley, J. J.; Penning, T. D.; Collins, P. W.; Rogier, D. J., Jr.; Malecha, J. W.; Miyashiro, J. M.; Bertenshaw, S. R.; Khanna, I. K.; Graneto, M. J.; Rogers, R. S.; Carter, J. S.; Docter, S. H.; Yu, S. S. Preparation of pyrazolylbenzenesulfonamides as cyclooxygenase inhibitors for treatment of inflammation. Cont-in part of US Patent US 6,413,960, 2002, 55 pp; CODEN: USXXAM US 6492411 B1 20021210.
46. Hwang, S. H.; Tsai, H.-J.; Liu, J.-Y.; Morisseau, C.; Hammock, B. D. Orally bioavailable potent soluble epoxide hydrolase (sEH) inhibitors J. Med. Chem. 2007, 50, 3825-3840 (Pubitemid 47292046)
47. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1 H -pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib) J. Med. Chem. 1997, 40, 1347-1365 (Pubitemid 27198082)
48. Watanabe, T.; Schulz, D.; Morisseau, C.; Hammock, B. D. High-throughput pharmacokinetic method: cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysis Anal. Chim. Acta 2006, 559, 37-44 (Pubitemid 43184285)
49. Hwang, S. H.; Morisseau, C.; Do, Z.; Hammock, B. D. Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 5773-5777 (Pubitemid 44486739)
50. Prasit, P.; Wang, Z.; Brideau, C.; Chan, C.-C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O'Neill, G. P.; Ouellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, I.; Tagari, P.; Therien, M.; Vikers, P.; Wong, E.; Xu, L.-J.; Young, R. N.; Zamboni, R.; Boyce, S.; Rupniak, N.; Forrest, M.; Visco, D.; Patrick, D. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4′- methylsulfonylphenyl)-3-phenyl-2(5 H)-furanone], an orally active cyclooxygenase-2 inhibitor Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778 (Pubitemid 29287387)
51. Maier, T. J.; Tausch, L.; Hoernig, M.; Coste, O.; Schmidt, R.; Angioni, C.; Metzner, J.; Groesch, S.; Pergola, C.; Steinhilber, D.; Werz, O.; Geisslinger, G. Celecoxib inhibits 5-lipoxygenase Biochem. Pharmacol. 2008, 76, 862-872
52. Gomez, G. A.; Morisseau, C.; Hammock, B. D.; Christianson, D. W. Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis Biochemistry 2004, 43, 4716-4723 (Pubitemid 38509092)
53. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents Nature 1996, 384, 644-648
54. Kanaan, S. A.; Saade, N. E.; Haddad, J. J.; Abdelnoor, A. M.; Atweh, S. F.; Jabbur, S. J.; Safieh-Garabedian, B. Endotoxin-induced local inflammation and hyperalgesia in rats and mice: a new model for inflammatory pain Pain 1996, 66, 373-379 (Pubitemid 26284008)
55. Brecker, L.; Pogorevc, H.; Griengl, H.; Steiner, W.; Kappe, T.; Ribbons, D. W. Synthesis of 2,4-diketo acids and their aqueous solution structures New J. Chem. 1999, 23, 437-446 (Pubitemid 29378818)
56. Talley, J. J.; Penning, T. D.; Collins, P. W.; Rogier, D. J., Jr.; Malecha, J. W.; Miyashiro, J. M.; Bertenshaw, S. R.; Khanna, I. K.; Graneto, M. J.; Rogers, R. S.; Carter, J. S.; Docter, S. H.; Yu, S. S. Preparation of pyrazolylbenzenesulfonamides as cyclooxygenase inhibitors for treatment of inflammation. Cont.-in-part of US Patent US 6,413,960, 2002, 55 pp; US 6492411 B1 20021210.
57. Liu, J. Y.; Tsai, H.-J.; Hwang, S. H.; Jones, P. D.; Morisseau, C.; Hammock, B. D. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation Br. J. Pharmacol. 2009, 156, 284-296